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"En droppe droppad i livets älv 
har ingen kraft till att flyta själv 
Det ställs ett krav på varenda droppe: 
Hjälp till att hålla de andra oppe!"  
Tage Danielsson  
 
  
ABSTRACT 
The school situation is one area identified as being affected during and after treatment 
for childhood cancer and only studied to a limited extent. A contributing factor to that 
school absence is not always recommended is uncertainty about whether it increases 
the risk of infection. Furthermore, there is a lack of valid instruments for the 
measurement of HRQOL in this population. The overall aim of this thesis was therefore 
to investigate the school situation and HRQOL of school-aged children (7-16 years) 
during initial cancer treatment and 4 to 6 years after diagnosis.   
 
The thesis includes four studies with a longitudinal design following a cohort of school-
aged children (n=126) diagnosed with cancer and starting chemotherapy and/or 
radiation therapy, response rate 87%. Data during initial cancer treatment were 
collected one month (T1), 2.5 months (T2) and 5 months (T3) after the start of initial 
treatment using a study-specific questionnaire to examine school attendance and a 
standardized instrument for the measurement of HRQOL: the Disabkids chronic 
generic module (DCGM-37). Study I reports on data quality and psychometric 
properties of the DCGM-37. Study II followed school attendance and HRQOL over 
three different weeks during the first 5 months of cancer treatment. Study III included 
children who were free from infection the day before the start of two observation 
periods (19 days) during initial cancer treatment. Demographic and clinical data as well 
as school attendance were analysed regarding the association to the start of 
antimicrobial treatment. A median of 5 years after diagnosis 63 of the former patients 
agreed to participate in a follow-up study of school situation and self-rated 
independence in survivors of childhood cancer (study IV). In study IV data were 
collected using telephone interviews with open-ended and structured questions. The 
survivors‟ responses from the structured questions were compared with those from age-
matched comparison group drawn from the general population (n=257). 
 
The evaluation of data quality and psychometric properties of the DCGM-37 (study I) 
indicates that it is a feasible instrument for children with cancer though dimensionality 
was not entirely supported. Furthermore, the results of study II-III revealed that school 
attendance significantly increased over the first 5 months of initial cancer treatment 
while self-reported HRQOL diminished, especially among the girls, which did not 
change throughout the first five months of treatment. Furthermore, HRQOL was 
positively related to school attendance. Hospital visits and fatigue were the two most 
common given reasons for school absence. Children who attended school did not 
appear to develop more infections than children not attending school. The results of 
study IV, conducted a median of 5 years after diagnosis, showed that despite that 62% 
of the survivors considered their school situation to be more or less the same as their 
peers‟ situation, a significant proportion reported difficulties in school because of 
physical and cognitive limitations. At follow-up, the survivors scored significantly 
higher on the independence dimension (i.e. on HRQOL) than they did during initial 
treatment and their scores were significantly higher than the controls.  
 
The present findings underscore the importance of psychosocial care and nursing for 
children undergoing cancer treatment and continued follow-up of survivors after 
completion of treatment. Furthermore, given the social benefits of school attendance, 
our results support the encouragement of school attendance during cancer treatment. 
Because of the relatively short time of the follow-up, it is not possible to draw 
conclusions about long-term outcome of the school situation for children with cancer.  
 
        Keywords: childhood cancer, health-related quality of life, school, antimicrobial 
treatments, survivorship 
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PREFACE 
In the late 1970s, as a rather newly registered nurse, I was working at the children‟s 
department in a ward with five beds allocated for children and adolescents with cancer. 
At that time, the main focus of paediatric oncology nursing was palliative care. My 
initial experience during the time when survival rates were very poor was that children 
and adolescents who eventually survived their cancer became lonely and were 
stigmatized by their illness. It seemed as though our society was not prepared to deal 
with survivors of childhood cancer, probably because of fear and lack of knowledge in 
the children‟s surroundings. Since then, childhood cancer treatment, together with the 
social situation for these children, has developed dramatically. However, many of these 
children still spend considerable time away from school and friends. Children treated 
for cancer worry about being away from school and friends, including having concerns 
about not being able to keep up with school work. In addition, there exists the risk of 
being forced to repeat a grade as well as the fear of losing their position among peers. A 
common reason for school absenteeism is fear that school attendance poses risks in 
terms of infections. Few researchers have investigated the susceptibility to infection 
among children treated for cancer. The consequence of this lack of knowledge is that 
health care professionals in paediatric oncology are uncertain as how to guide these 
children and their families to take part in social activities, including school. As long as 
it is unclear how the social life of children with cancer should be like in order not to 
pose risks, it is likely that school absence will remain a problem. The rational for this 
thesis is based on the fact that little is known about the school situation during and after 
childhood cancer as well as about the relation between school attendance and infection.  
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BACKGROUND 
DIAGNOSED WITH CANCER IN CHILDHOOD 
When a child is diagnosed with cancer the whole life of an entire family changes 
completely (Collins, Devine et al. 2002; Björk, Wiebe et al. 2005). While parents of 
children diagnosed with cancer are undergoing an extremely distressing experience, 
they constitute the most important support of their child (Boman, Lindahl et al. 2003). 
Furthermore, due to shorter hospital admissions a great responsibility in caring for the 
child rests on the parents resulting in major demands on a close collaboration and 
support from health care. Even siblings experience a difficult time with ambivalent 
feelings concerning the constant worry and of always having to make way for the needs 
of their sibling (Nolbris, Enskär et al. 2007). 
 
Having cancer during childhood typically implies being bound to hospital and 
treatments for a long period (Enskär and von Essen 2007). Thus, it is difficult to make 
plans for more than one day at a time. It also means that the young patient is highly 
dependent on others, particularly parents and health care professionals (Landolt, 
Vollrath et al. 2006). Children with cancer are living with uncertainty not only from the 
unknown outcome of the cancer but also in the context of treatment, adverse events and 
procedures and their effects (Stewart 2003). 
 
Living with uncertainty has been described by children with cancer and their parents 
(Stewart 2003; Al-Gamal and Long 2010). Such uncertainty is known to cause the 
children emotional distress, such as worry and fear, and makes it impossible to prepare 
themselves for negative events (e.g., painful procedures and side effects of treatment). 
Children and adolescents (8 to 19 years) undergoing treatment for cancer were asked to 
indicate whether they had experienced any distressing event in relation to disease and 
treatment (Hedström, Haglund et al. 2003). The most frequent examples of 
experiencing distressing events given by children 8 to 12 years of age were nausea, oral 
medication, worrying about death, confinement and feelings of alienation. For children 
between 13 and 19 years, the distressing events most frequently mentioned were 
nausea, pain from diagnostic procedures and treatments and a changed appearance. 
 
During recent decades, paediatric cancer care has undergone a major change in the 
form of a shorter length of time admitted to hospital and significantly extended 
outpatient care. However, the children still spend a great deal of time at hospital. In 
addition to the treatment of the primary disease and of adverse events, almost all 
medical treatment protocols include time-consuming examinations that have to be done 
between each treatment. Consequently, contact with school and friends are periodically 
limited. During this time, most children with cancer experience changes in appearance 
and may therefore be concerned about how friends will react and of not being accepted 
when they return to school (Stewart 2003). Erik Homburger Eriksson (1986) suggested 
that development of self-identity is dependent on the identity of the group (e.g., school 
class and friends) (Homburger Eriksson 2004). Eriksson describes the personality 
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development in terms of eight stages with unique age-specific psychosocial 
characteristics. The development in one stage influences the progress in the stages that 
follow. The stage of latency (6-12 years) is primarily characterized by activity and 
action. Neighbourhood and school are important factors during this stage. However, a 
chronic illness often leads to inactivity and to changes in appearance, which may result 
in the child perceiving that he or she is different from others. Adolescence (12-18 
years) covers puberty and is largely characterized by searching for a meaning and ego 
identity. Appearance and socialization with peers are of great importance while parents 
are considered to show less understanding (Homburger Eriksson 2004). A chronic 
illness during adolescence may also interfere with the development of autonomy and 
emancipation from the parents.  
 
DIAGNOSES AND TREATMENT 
The annual incidence of cancer in children and adolescents in Sweden is 
approximately 300, with very little change over the years (Gustafsson, Heyman et al. 
2007): the survival rate is today estimated to 80% (Gatta, Corazziari et al. 2003). The 
majority of cancers that affect children do not occur in adults and the aetiology of 
childhood cancers is largely unknown. Childhood cancer is most prevalent in 
preschool age, whereas about one sixth occurs in children of school age. Children 
with leukaemia represent the largest group of childhood cancers, of which acute 
lymphoblastic leukaemia (ALL) is the most common. The diagnoses most common in 
children of school age are ALL, Ewing sarcoma, soft tissue sarcoma and non-
Hodgkin's lymphoma (NHL). Osteosarcoma, acute myeloid leukaemia (AML) and 
Hodgkin lymphoma occur more frequently during puberty. Tumours of the central 
nervous system (CNS) are evenly distributed across all ages (Gustafsson, Heyman et 
al. 2007).  
 
At time of diagnosis, children with cancer often exhibit a wide variety of diffuse 
symptoms. Children with leukaemia, for example, often present with a short history of 
fatigue, infection, mucosal bleeding and hematoma. The most common symptom of a 
solid tumour is pain in the affected area. However, before diagnosis, children diagnosed 
with tumours of the CNS often have a long anamnesis with straining symptoms of 
headache, energy loss, lost appetite and difficulties with balance and coordination 
(Rasco Baggott 2001). Consequently, some children may perceive that they were 
healthy prior to receiving treatment, whereas others may feel a great relief because of 
the good treatment response. 
 
The high survival rate in childhood cancer is mainly due to chemotherapy that 
constitutes the majority of the treatment protocols, either exclusively or in combination 
with surgery or radiotherapy. Chemotherapy in children is often more aggressive than 
in adults, partly because of a better tolerance of the medication in children (Smith and 
Ho 1996). The treatment of ALL, AML and NHL is mainly chemotherapy of varying 
intensity and in treatment of Hodgkin‟s lymphoma and Ewing's sarcoma often in 
combination with radiation therapy.  Children with CNS tumours are the only childhood 
tumours that primarily undergo surgery, usually followed by radiotherapy and 
 4 
chemotherapy (Rasco Baggott 2001). Because of the risk of irreversible injuries, efforts 
are made to minimize radiation therapy in the treatment of children. However, 
radiotherapy is often required in the treatment of children with CNS tumours (Wallace 
2004). Children with solid tumours other than CNS tumours and who require surgery 
are normally treated with chemotherapy pre-operatively and most often 
postoperatively. Osteosarcoma is a primary skeletal tumour arising from bone-forming 
cells. The treatment consists of intensive chemotherapy, both pre- and postoperatively. 
The surgically removed part of the bone is usually replaced by prosthesis and total 
amputations are nowadays rare (Lietman and Joyce 2010). Additionally, many of the 
medical treatment protocols used in childhood cancer include treatment with 
corticosteroids. 
 
In Sweden, all children and adolescents (i.e. newborns to 18 years of age) with cancer 
are diagnosed at one of six Paediatric Oncology Centres (Umeå, Uppsala, Stockholm, 
Linköping, Gothenburg and Lund). Most of the treatment is provided at the centre and 
occasionally at the patients‟ local hospital in consultation with the centre. The type of 
cancer is classified according to the International Classification of Childhood Cancer 
and the treatment is given according to national and international treatment protocols 
sanctioned by the Swedish Childhood Leukaemia Group (SBLG), the Swedish 
Childhood Solid Tumour Group (VSTB) and the Swedish Childhood CNS Tumour 
Group (VCTB).  
 
Early and late complications of treatment  
Complications of treatment, both acute and later in life, differ from patient to patient 
and depend on type of cancer and treatment (Collins, Devine et al. 2002; Oeffinger, 
Mertens et al. 2006). Chemotherapy primarily affects fast growing cells, and 
consequently, side effects of treatment arise in the normal cells that divide frequently 
(Rasco Baggott 2001). The acute symptoms include nausea and vomiting, loss of 
appetite, constipation, oral mucositis, infections with fever, fatigue and loss of strength, 
pain, leg weakness and psychological distress (Collins, Devine et al. 2002; Sala, 
Pencharz et al. 2004; Christensen, Nielsen et al. 2005; Hedström, Ljungman et al. 2005; 
Selwood 2006; Wicki, Keisker et al. 2008; Gomber, Dewan et al. 2010).  Shortly after 
the start of cancer treatment, most of the children experience a changed appearance. 
One of the most visible and at first most distressing side effects from treatment is hair 
loss (Hedström, Ljungman et al. 2005). Practically all children treated with 
chemotherapy lose their hair as well as those treated with radiotherapy of the scull, with 
the only difference that the hair starts to grow back after chemotherapy but not always 
after radiotherapy (Rasco Baggott 2001; Oeffinger, Mertens et al. 2006). Children with 
certain cancer diagnoses often experience nutrition problems with either gained or lost 
weight. A frequent complaint is not being able to enjoy food due to chemotherapy 
effects with changed taste perception and increased sensitivity to smells (Moody 2006). 
Corticosteroids, periodically included in several childhood cancer treatment protocols, 
are often associated with a constant demand for food. Furthermore, during treatment 
with corticosteroids, many children experience frequent mood swings from euphoria to 
severe dysphoria. 
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Neutropenia is one of the most frequently reported side effects of cancer therapy and 
therefore, children undergoing treatment for cancer may be particularly vulnerable to 
infections. Depending on the dose intensity of the chemotherapy regimen, bone marrow 
function is suppressed, resulting in a low absolute neutrophil count (ANC) that poses a 
high risk of infection. An ANC of <0.5 x 10
9
/l is considered as severe neutropenia 
(WHO grade IV). The risk of infections increases with the depth and duration of 
neutropenia. Children with neutropenia who develop fever may be at risk of significant 
complications and even death from infection (Santolaya, Alvarez et al. 2007). Increased 
susceptibility to infections in children with cancer has been suggested to be associated 
with higher intensity of chemotherapy and central venous catheters (CVC) (Haupt, 
Romanengo et al. 2001; Wicki, Keisker et al. 2008), less time since diagnosis, bone 
marrow involvement, prior episodes of febrile neutropenia (Wicki, Keisker et al. 2008), 
nutritional state (Israels, van de Wetering et al. 2009) and genetically determined 
variations of the immune system (Neth, Bajaj-Elliott et al. 2005).  
 
Social aspects of susceptibility to infections, such as school attendance, are rarely 
mentioned and recommendations during childhood cancer treatment vary, usually being 
based on diagnosis, laboratory results or the child‟s general condition (Christensen, 
Nielsen et al. 2005). An increased risk for infections has been reported among healthy 
children in kindergarten and pre-school (Nafstad, Hagen et al. 1999) but little is known 
about the risk of infections for school-aged children and children undergoing treatment 
for cancer.  
 
Traditionally, standard care of children with febrile neutropenia is immediate 
hospitalization and the collection of blood cultures, followed by treatment with 
intravenous broad-spectrum antibiotic agents for at least 24 hours. Research has 
focused on identifying those children at low-risk for severe complications during 
febrile neutropenia in order to limit time of hospitalization and use of antimicrobial 
treatment (Hakim, Flynn et al. 2010; Macher, Dubos et al. 2010; Agyeman, Aebi et al. 
2011). The results, however, are not conclusive and consequently the management of 
children with febrile neutropenia in clinical practice vary (Boragina, Patel et al. 2007). 
 
In a longer perspective childhood cancer survivors have been reported to be three times 
more likely to experience at least one chronic health condition and five times more 
likely to experience two chronic health conditions compared with sibling controls 
(Oeffinger, Mertens et al. 2006). Furthermore, almost 30% of the survivors are reported 
to have severe or life-threatening conditions. Survivors of bone tumours are most likely 
to experience physical limitations; survivors of CNS tumours are most likely to 
experience cognitive, visual and auditory impairments; and survivors of Hodgkin‟s 
lymphoma are most at risk for secondary cancers and heart failure. Radiotherapy for 
growing children, especially of the brain, is always associated with risk of significant 
long-term effects, such as endocrine (growth and thyroid) and neurological 
abnormalities (Mitby, Robison et al. 2003; Barrera, Shaw et al. 2005). 
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CARE 
When a child is diagnosed with cancer, a long period of intensive nursing contact 
begins, where a trustful relationship between the nurses and the child and family is 
crucial. Caring for a child with cancer will involve the care and support of a whole 
family, e.g. parents and siblings (Nolbris, Enskär et al. 2007; Norberg and Boman 
2007; Björk, Wiebe et al. 2009). The nurses should provide the family with information 
and education concerning childhood cancer, treatment and treatment-related 
complications (Rasco Baggott, 2002). The families are taught to prevent side effects 
from treatment, how to alleviate the side effects and how to know when it is urgent to 
contact the treating hospital. Fever during treatment may, for example, be an 
emergency and it is important that the child and family are made aware of this. The 
paediatric oncology nurses have an important role in the prevention of acute side 
effects from treatment and must make sure they are properly treated if side effects do 
occur (Rasco Baggott, 2002).   
 
One of the most important and challenging tasks for paediatric oncology nurses is to 
ensure the child‟s right to receive information. Considering the large variation in ages 
among treated children, good knowledge of child development is required. Information 
to children is not given at a certain time but continuously at moments when the child 
indicates being receptive and it is not possible to use general routines. Nurses caring for 
children with cancer have an excellent opportunity to establish close contact with the 
child while carrying out treatment and other procedures. By carefully listening to the 
child and by posing counter questions, it is possible for the nurse to identify the 
concerns of the individual child. Moreover, it makes it possible to respect those 
children that do not want to have certain information. Information to children needs to 
be frequently repeated, not only to make sure that it has been correctly understood but 
also because children are undergoing constant development and so does their focus of 
concern. All children need to be well prepared before procedures are introduced and the 
way the nurse performs painful procedures and responds to the child is crucial to how 
the child manages these procedures in the future (Stephens, Barkey 1999; Heden, von 
Essen 2009).  
 
Missing school is considered a major concern for children when undergoing treatment 
for cancer (Hedström, Ljungman et al. 2005; Moody 2006). Poor communication 
among nurses, school personnel and parents has been identified as a major barrier in 
facilitating the cancer patient‟s return to school (Moore, Kaffenberger et al. 2009). All 
paediatric oncology nurses have the responsibility to facilitate and support contact with 
the child‟s school and friends. Moreover, in Sweden the national network of consultant 
nurses in paediatric oncology, financed by the Foundation of Märta and Gunnar V 
Philipson and the Swedish Childhood Cancer Foundation, is especially focused on 
issues concerning the social life of children with cancer. The consultant nurses offer 
visits to the patients‟ schools at the time of diagnosis, at relapsed disease, in case of no 
hope for cure and on request. In close collaboration with the family general information 
about childhood cancer and the individual child‟s treatment are provided to school 
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personnel and classmates. The aim is to prevent children diagnosed with cancer to 
become separated from a normal social life. The importance of an early, constantly 
evaluated individualized study plan for the child, defined actions to maintaining close 
contact between school and the child and his or her family and to minimize absence 
from school are emphasized.  
 
SCHOOL SITUATION 
The Swedish school system 
The Swedish public school system consists of compulsory and non-compulsory 
schooling. Compulsory education includes a 9-year regular comprehensive school. 
Non-compulsory education comprises the preschool class, upper secondary school and 
adult education. Compulsory school entry is normally at the age of 7 years and finishes 
at the age of 16 years. Education throughout the public school system is free. 
Approximately 12% of compulsory school students attend one of the country‟s 
approved independent schools (The Swedish National Agency for Education, 2010).  
 
Social life including school situation 
To investigate the impact of social life from health conditions measures are used in 
which individuals are asked to estimate their role in relation to social function and well-
being. The term social life includes different aspects of social life, aspects that are often 
assessed in different combinations, referring to different, often overlapping concepts. 
One dimension of health-related quality of life (HRQOL) is social functioning, which 
focuses on measurement of inter-personal functioning in peer relations (Varni, Seid et 
al. 1999; Eiser 2007). Psychosocial function, according to Bullinger et al (2002), 
coping, social support, perceptions of care and socio-economic factors (Bullinger 
2002). Social outcome, another concept frequently used in connection with 
measurements of Quality of life (QOL), includes variables such as having and using 
friends as confidants (Barrera, 2005) and marital, educational and employment status 
(Ishida, Honda et al. 2011). Johannisdottir et al. (2010) add items related to parenthood 
and independent living, a combination of variables sometimes referred to as social 
adjustment (Boman and Bodegård 2004; Johannsdottir, Hjermstad et al. 2010). Studies 
evaluating children undergoing cancer treatment have reported that social life, 
including the school situation, may be negatively affected by disease and treatment 
(Lähteenmäki, Huostila et al. 2002; Hedström, Ljungman et al. 2005; Moody 2006). 
Few studies, however, have investigated school attendance and its relation to HRQOL 
during childhood cancer treatment. While absent from the community, school children 
may be provided schooling at hospital and at home by the community school. In two 
qualitative studies one of children undergoing treatment for cancer and one of cancer 
survivors, homebound schooling was found to be inadequate and isolating (Bessel 
2001; Searle, Askins et al. 2003). 
 
Few researchers have studied the implications of childhood cancer survivorship on the 
school situation (Sheinfeld Gorin 2009). In a Canadian retrospective mail survey 
parents of survivors of childhood cancer (aged 17 years or less) reported 10 years or 
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more after diagnosis (n=800) that their child had repeated a grade significantly more 
often than a group of matched controls (21% vs. 9%). These same children attended a 
learning disability programme more often (19% vs. 7%) or attended a special education 
programme more often than the matched controls (20% vs. 8%). In addition, more 
parents of survivors of childhood cancer reported that their child had educational or 
other school problems (46% vs. 23%) (Barrera, Shaw et al. 2005). In an American 
study using self-reports from participants aged 18 years or over and from parents of 
participants aged younger than 18 years (n=12430) long-term survivors were compared 
with a sibling control group 5 years or more after diagnosis. The authors found that 
23% of the long-term survivors versus 8% of the siblings attended special education 
programmes and that those diagnosed before the age of 6 years (mostly associated with 
females), treated for tumours in CNS and treated with intracranial methotrexate and/or 
cranial radiation were more likely to attend special education programmes. Long-term 
childhood cancer survivors of leukaemia, CNS tumours, NHL and neuroblastoma were 
significantly less likely to complete high school and college than siblings. However, 
among those attending special education programmes only long-term survivors of CNS 
and kidney tumours were less likely than siblings to complete high school and only 
those who had received cranial radiation therapy were less likely to have completed 
college (Mitby, Robison et al. 2003). Other studies have shown that survivors of 
rhabdomyosarcoma (Punyko, Gurney et al. 2007) and sarcoma of the lower extremities 
(Nagarajan, Neglia et al. 2003) have good high school graduation rates when compared 
with siblings. When long-term survivors and parents were asked to respond to a 
question about reasons for the need to attend a special education programme, the 
response alternative „due to missed school‟ was more frequently chosen among 
survivors of all diagnoses compared with siblings and were most associated with 
survivors diagnosed before the age of 16 years and with sarcoma (bone and soft tissue). 
The response alternative „low test scores‟ was most associated with leukaemia, CNS, 
Wilms and neuroblastoma (Mitby, Robison et al. 2003). Knowledge about the 
survivors‟ experiences of how the school situation is affected by them having had 
cancer is still limited, however. Feelings of being different (Prouty, Ward-Smith et al. 
2006; Enskär and Bertero 2010), the importance of support from others and that school 
attendance is associated to living a normal life (Prouty, Ward-Smith et al. 2006) have 
all been noted by adult survivors after childhood cancer. 
 
HEALTH-RELATED QUALITY OF LIFE  
In this thesis HRQOL is viewed as a multidimensional construct with physical, 
emotional, mental, social and behavioural aspects of well-being and function as 
perceived by patients, as defined by the Disabkids group (Bullinger 2002). 
 
Measurement of health and quality of life in children  
Because of a general lack of valid instruments for self-reports, assessment of HRQOL 
in children and adolescents with cancer is often based on proxy reports (Eiser, Eiser et 
al. 2005; Upton and Eiser 2006; Fluchel, Horsman et al. 2008). One of the instruments 
most frequently used in children with cancer is the Paediatric Quality of Life Inventory 
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(PedsQL) for children aged 5-18 years. The PedsQL, which is a self-report 
questionnaire, includes a generic scale and a disease-specific cancer module (Varni, 
Seid et al. 2001). Another instrument used in children with cancer is the revised 
Memorial Symptom Assessment Scale (MSAS) for children aged 7 to 12 years 
(Collins, Devine et al. 2002). The MSAS is a self-report questionnaire that assesses 
established cancer-related symptoms (Collins, Devine et al. 2002). Follow-up studies 
after cancer treatment have commonly used generic and domain-specific instruments 
developed for an adult population, such as the Short Form Survey (SF-36) (Jörngården, 
Mattsson et al. 2007; Sundberg, Doukkali et al. 2010), the TNO-AZL Children‟s 
Quality of Life (TACQOL) questionnaire (Landolt, Vollrath et al. 2006) and the 
Hospital Anxiety and Depression scale (HADS) (Jörngården, Mattsson et al. 2007). 
These instruments also provide validated normative data for adolescents and young 
adults in the general population (Jörngarden, Wettergren et al. 2006). The above-
mentioned instruments contain no items or only a limited number of items concerning 
school. Kidscreen is a generic self-report HRQOL instrument. The instrument contains 
school items designed for children 8-18 years and has recently been used to measure 
HRQOL in childhood cancer survivors close to completion of treatment (Engelen, 
Koopman et al. 2011).  
 
HRQOL during and after treatment 
Childhood cancer and its treatment often cause physical, social, emotional and 
cognitive concerns and may thus affect HRQOL (Doward and McKenna 2004; Rajmil, 
Herdman et al. 2004). Studies that have followed HRQOL in children diagnosed and 
treated for cancer the first year after diagnosis have reported emotional distress (Eiser, 
Eiser et al. 2005; Hedström, Ljungman et al. 2005; Landolt, Vollrath et al. 2006; 
Jörngården, Mattsson et al. 2007), diminished physical and functional status (Landolt, 
Vollrath et al. 2006; Engelen, Koopman et al. 2011) and lack of vitality among the 
young cancer patients (Eiser, Eiser et al. 2005; Jörngården, Mattsson et al. 2007). 
Female adolescents in the general population have reported poorer HRQOL than males 
(Bisegger, Cloetta et al. 2005; Jörngarden, Wettergren et al. 2006) and the same gender 
difference has been demonstrated in children treated for cancer (Landolt, Vollrath et al. 
2006). Results from a recent study showed that, in comparison with norms, physical 
well-being was worse among children aged 8-18 years who had completed childhood 
cancer treatment 2 months earlier (Engelen, Koopman et al. 2011). However 
adolescents aged 12-18 years scored significantly better than norms on the following 
dimensions of HRQOL: parent relation and home life, school environment, bullying 
and financial resources. 
 
In a longer perspective findings of HRQOL among childhood cancer survivors are not 
conclusive in the sense that some studies have shown that survivors reported equal or 
even better HRQOL controls without cancer experience (De Clercq, De Fruyt et al. 
2004; Jörngården, Mattsson et al. 2007), whereas others reported considerable impact 
on HRQOL (Armstrong, Stovall et al. 2010; Dowling, Yabroff et al. 2010). A study of 
long-term survivors of childhood cancer found that 68% reported at least one negative 
consequence and 50% at least one positive consequence after the cancer experience 
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(Sundberg, Lampic et al. 2009). Some studies have shown that childhood cancer 
survivors who reach adulthood do not manage as well as controls regarding 
employment (Johannsdottir, Hjermstad et al. 2010), marriage (Dieluweit, Debatin et al. 
2010; _ENREF_67Pivetta, Maule et al. 2011) and parenthood (Dieluweit, Debatin et al. 
2010; Johannsdottir, Hjermstad et al. 2010; Pivetta, Maule et al. 2011_ENREF_67).  
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AIMS 
The overall aim of this Swedish nationwide longitudinal study was to investigate the 
school situation and HRQOL among children during and after treatment for cancer.  
 
The specific aims of the present thesis were: 
 To evaluate data quality and psychometric properties of an instrument for the 
measurement of HRQOL using the DISABKIDS Chronic Generic Module 
(DCGM-37) among school-aged children with cancer (Study I). 
 
 To follow HRQOL, school attendance and social interaction with friends in 
children with cancer and explore the potential relation between HRQOL and 
school attendance. Furthermore, the study investigated self-reported reasons 
for not attending school and not meeting friends (Study II). 
 
 To investigate the relation between school attendance and infection in children 
undergoing treatment for cancer (Study III). 
 
 To investigate the school situation and self-rated independence in survivors of 
childhood cancer (Study IV).  
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METHODS 
DESIGN 
A longitudinal design was used in this nationwide cohort study. Study I-III are 
descriptive and comparative and have a quantitative approach. Study IV includes both 
quantitative and qualitative data.  
 
STUDY SUBJECTS 
All children in Sweden attending compulsory school (aged 7 to 16 years) and who were                                                                                                                                                           
diagnosed with cancer and starting chemotherapy and/or radiation therapy from 
January 2004 to May 2006 were eligible for inclusion in the studies. Children treated 
with stem cell transplantation or surgery as single treatment and those that did not 
understand Swedish were excluded. One hundred and forty-five children and 
adolescents were eligible for participation, of which 126 (87%) consented.  
 
 
Figure 1. Overview of the inclusion of participants in study I-III 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Eligible and invited Study I-
III  
N=145 
 
Declined participation 
n=19 
Included study I-III                    
n=126 
First assessment, T1                
n=117                                     
(missing data n=4) 
 
 
 
     Terminated participation after T1 
      n=5                           
 
Second assessment, T2 
n=112                           
(missing data n=5) 
T  Terminated participation after T2 
      n=11                            
Third assessed week, T3                  
n=101                                
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Study I  
In study I 83 of the 126 children that consented to participate completed the DCGM-37 
at 2.5 months after the start of treatment (T2) and 87 five months after start of treatment 
(T3).   
 
Study II    
Of the 126 children, 101 (70%) participated in all three assessment weeks (T1, T2, T3) 
and were included in study II (Figure1). The median age of the participants was 12 
years (range 7 to 16 years). The participants from study I are included in the 101 
participants in study II. 
Figure 2. Overview of the inclusion of survivors and controls in study IV 
 
 
Study III  
Of the 101 participants included in study II those who were free from infection the day 
before the start of two observation periods of 19 days at TI (n=89) and T2 (n=89) were 
included in study III. 
 
 
Study IV  
Survivors 
A median of 63 (range 50 to 74 months) months post-diagnosis, 92 of the former 
childhood cancer patients were eligible and invited to participate in a follow-up. Sixty-
three (68%) of the 92 survivors, now aged from 12 to 22 years (median 17 years, range 
12 to 22 years), agreed to participate in Study IV (Figure 2).  
 
 
 
 
  
 
 
  
 
 
  
 
  
 
 
 
 
 
 
 
       Deceased                                
n=23 
 
Invited survivors                           
n=92 
Participating survivors                   
n=63 (68%) 
Declined participation               
n=29 
Excluded n=3 
Cognitive dysfunction n=2 
Unidentifiable address n=1 
Excluded n=24 
Non-Swedish speaking n=5 
Cognitive dysfunction n=4 
Prior cancer experience n=1 
Living abroad n=9 
Unidentifiable address n=5 
 
Invited controls  
n=476 
 
Declined participation 
n=169 
 
Participating controls              
n=257 (54%) 
 
Survivors (from study I-III)                   
N=118 
 
Comparison group  
N=500 
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Comparison group 
A sample of 500 young persons (250 girls and 250 boys) with a median age of 16 
(range 11-23 years) years was randomly selected from the Swedish population register 
(SPAR). Twenty-four persons were excluded and 257 (54%) of the remaining 476 
agreed to participate (Figure 2).  
 
DATA COLLECTION 
The four studies included in this thesis are presented in Table 1. 
 
During initial treatment, data were collected using two questionnaires, one study-
specific questionnaire measuring school attendance and social interaction with friends 
and one standardized instrument (i.e. the DCGM-37) measuring HRQOL. The time 
points for data collection are displayed in Figure 3. 
 
 
 
 
 
 
 
 
 
 
 
                                                                              
  
0              1              2            3              4              5              6         //        4               5                6 
Treatment start                                                            Months       //       Years after diagnosis                       
 
Figure 3. Time points for data collection study I-IV 
 
Data from the survivors of childhood cancer were collected by telephone interviews 
that included both open-ended and structured questions (study-specific and the DCGM-
37 dimension Independence). Two survivors accepted participation provided that the 
questionnaire was sent home by mail for self-administration. The time points for data 
collection are presented in Figure 3. 
 
Data from the comparison group were only based on structured questions (study-
specific and the DCGM-37 dimension Independence) and in most cases collected via 
telephone interviews though 27 persons received the questionnaires by mail for self-
administration. 
 
 
 
T1 
School 
attendance 
  
T2 
School 
attendance 
HRQOL 
 
 
 
T3 
School 
attendance 
HRQOL 
 
 
Follow-up 
School 
Independence                      
Demographics 
 
Demographic and clinical data from medical records 
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Table 1. Summary of the four studies with regard to study outcomes, number of 
participants, measures and analyses    
Study Study outcomes Number of 
participants 
Measures Analyses 
I Data quality and 
psychometric properties 
of Disabkids chronic 
generic module (DCGM-
37) 
n=170  
(pooled 
data) 
DCGM-37 
Medical records 
Descriptive statistics 
Multi-trait scaling analyses   
Cronbach‟s alpha 
Student‟s unpaired t-test 
Effect sizes 
 
II School attendance, social 
interaction with friends 
and reasons for school 
absence 
n=101 Study-specific 
questionnaire 
regarding school 
attendance 
Medical records 
DCGM-37 
Descriptive statistics  
Cronbach`s alpha 
Chi-square statistics 
Friedman‟s test 
Student‟s unpaired t-test 
Pearson‟s correlation 
coefficient   
HRQOL T2, n=83 
T3, n=87 
III Relation between school 
attendance and infection 
n=101 Study-specific 
questionnaire 
regarding school 
attendance 
Medical records 
Chi-square
 
statistics 
Fisher‟s exact test 
Mann-Whitney U test 
Kaplan-Meier method 
The log-rank test 
IV School situation and self-
rated independence 
Survivors, 
n=63  
Study-specific   
questionnaire with 
both open-ended and 
structured questions 
regarding school 
situation and 
perceived 
susceptibility to 
infections 
The DCGM-37 
dimension 
Independence 
Content analysis  
Descriptive statistics  
Chi-square
 
statistics  
Mann-Whitney U test 
Cronbach`s alpha 
Student‟s paired t-test 
Student‟s unpaired t-test 
Effect sizes 
 
Comparison 
group,      
n= 257  
Study-specific   
questionnaire with 
structured questions 
regarding school 
situation and 
perceived 
susceptibility to 
infections 
The DCGM-37 
dimension 
Independence 
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Measures 
Disabkids Chronic Generic Module (study I, II, IV)  
The DCGM-37 was designed to assess HRQOL in children and adolescents with 
chronic conditions. The instrument was developed within a European collaboration 
involving seven countries and six languages (Dutch, English, French, German, Greek 
and Swedish) to measure HRQOL in seven chronic conditions (Asthma, Arthritis, 
Atopic Dermatitis, Diabetes, Cystic Fibrosis, Cerebral Palsy and Epilepsy). When this 
project was started, the DCGM-37 had not been used in children with cancer (Bullinger 
2002). The instrument consists of 37 items that measure mental, social and physical 
domains of HRQOL: Independence (autonomy and living without impairments), 
Physical Limitation (functional limitations, perceived health), Emotions (emotional 
worries and concerns), Social Exclusion (stigma, feeling left out), Social Inclusion 
(acceptance of others, positive relationships) and Treatment (perceived emotional 
impact of treatment). The items refer to the four previous weeks and are answered on a 
5-point Likert scale ranging from 1 (never) to 5 (very often). In accordance with the 
standard scoring algorithms of the instrument, raw scores are coded for each question, 
summed and transformed into a scale from 0 (worst possible HRQOL) to 100 (best 
possible HRQOL). In the studies included in this thesis the version from 2004 was 
used. In study IV the dimension Independence (six items) was included in the 
assessments of the survivors and controls. 
 
The DISABKIDS Smiley version was developed to assess HRQOL and level of 
distress in children with chronic conditions aged 4 to 7 years. The participating children 
that were not considered by the parents and the nurse to be able to manage the DCGM-
37 were presented the Smiley version. This version consists of six items with a five-
point rating scale of smiley face responses. The happiest face receives the highest score 
and the unhappiest face the lowest (The European DISABKIDS Group 2006). Eleven 
children (7-14 years old) fulfilled the Smiley version on either one or both occasions. 
(Results from the Smiley version are not included in this thesis). 
 
Study-specific questionnaire regarding school attendance (study II, III) 
To measure school attendance and socialization with friends during treatment for 
cancer a study-specific questionnaire was developed. The questionnaire consisted of 
eight items: two of the eight items measure number of days at school and attended 
lessons each day; three items assess the number of friends the child played or interacted 
with and the place and length of the social interaction; two items concern reasons for 
not attending school and seeing friends; and one item asks who completed the 
questionnaire. Six response alternatives were presented for not attending school and not 
seeing friends: “hospital visits”, “infections”, “fear of getting infections”, 
“fatigue/tiredness”, “fear of other people‟s reactions” and “other reasons”. To test the 
face validity of the questionnaire 10 parents to children undergoing cancer treatment at 
Astrid Lindgrens Children‟s Hospital, Karolinska University Hospital, Stockholm were 
asked to fill out the questionnaire on two separate occasions. The parents‟ comments on 
the 10 questions resulted in some minor modifications of the questionnaire.  
  
   17 
Study-specific questionnaire regarding school situation and the person’s perceived 
susceptibility to infections (study IV) 
The telephone interviews conducted with the survivors and the comparison group 
included study-specific questions. Three of the study-specific questions are presented 
below: “How important do you consider school to be in your life?” “How much have 
you been absent from school during the past month?” “If you compare yourself to your 
peers do you think that you catch colds more easily?” Demographic questions (living 
situation, siblings, main occupation, education) were also included in this 
questionnaire. 
 
Open questions regarding the school situation (study IV) 
Semi-structured telephone interviews with open-ended questions were conducted with 
the survivors. The interviews were performed using an interview guide with follow-up 
questions to clarify the meaning of statements. Two of the posed questions in the 
telephone interviews are presented here: “Because of your cancer experience, do you 
think things are different in school for you today compared to your peers?” “When 
thinking back on life during the time of your cancer treatment, what do you first think 
about?”  
 
Medical records  
Disease- and treatment-related data were collected from the participants‟ medical 
records. The information collected included demographic data (gender, date of birth, 
siblings in pre-school age) and information on diagnosis and cancer treatment (type, 
date of diagnosis, treatment protocol and date of treatment start). Furthermore, 
antimicrobial treatment (number, type, duration and, if applicable results from 
microbiological cultures), prophylaxis (antimicrobial or granulocyte colony-stimulating 
factor), laboratory reports (absolute neutrophil cell count, ANC) and invasive devices 
(number, type) were retrieved for each observation period of 19 days.  
 
DATA ANALYSIS 
The data analyses performed in the different studies are summarized in Table I (page 
15). All statistical calculations were conducted using the Statistical Package for Social 
Sciences (SPSS Inc, Chicago, IL, USA) for windows, version 18.0 and StatView 5.0.1 
software (© 1992-98 SAS Institute, Inc. Cary, NC, USA).  
 
Descriptive statistics (frequencies, percentages, medians and ranges, means and 
standard deviations) were used to characterize measured variables. To determine 
differences in categorical variables chi-square statistics were performed or, in cases of 
small numbers, Fisher‟s exact test was applied. Differences in medians were 
determined by the Mann-Whitney U test and Friedman‟s test (over time). Cronbach‟s 
alpha values were calculated to estimate the internal consistency reliability of the 
DCGM-37. Alpha values >0.70 are considered acceptable though >0.80 are preferred 
(Nunnally JC 1994). Mean value differences in variables normally distributed were 
analyzed with Student‟s unpaired and paired t-test. Effect sizes (ES) were calculated to 
underscore the clinical importance of potential mean value differences. ES is calculated 
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by dividing the mean value difference between two groups with the standard deviation. 
According to Cohen, an ES=0.20-0.50 indicates a small difference, ES=0.51-0.80 a 
medium difference and ES>0.80 a large difference (Cohen 1988). Associations 
between variables were analyzed with Pearson‟s correlation coefficient, and when 
appropriate, Spearman‟s rank correlation coefficient. P-values <0.05 were considered 
statistically significant.  
 
Study I 
Descriptive and psychometric analyses in study I are based on pooled data from T2 
(n=83) and T3 (n=87). When sample sizes are small, pooling of data is recommended 
to increase precision of the estimates (Ware and Gandek 1998; Westen and 
Weinberger 2004).  
 
Feasibility of the DCGM-37 was examined through the nurses‟ comments on the items, 
as well as by oral and written comments given by the participants and their parents.  
 
Data quality of the DCGM-37 was evaluated by examining the number of missing item 
responses (Ware and Gandek 1998). Missing responses of up to 10% have been 
suggested as acceptable (Saris-Baglama 2004.). Simple summation of item scores into a 
total score is supported by similar item means and standard deviations within each 
dimension and corrected item-total correlation coefficients exceeding 0.3 (Ware and 
Gandek 1998). Furthermore, items within each dimension are considered to represent 
the same latent variable if corrected item-total correlations are ≥0.40 (Ware and 
Gandek 1998). The distribution of dimension scores is considered supported with floor 
and ceiling effects <15% (McHorney and Tarlov 1995) and alpha values >0.70 
(Nunnally 1994). The internal construct validity of the DCGM- 37 was examined by 
multi-trait scaling analysis with correction for overlap. An item‟s corrected item-total 
correlation >0.40 with the dimension it is hypothesized to belong to and a weaker 
correlation with all other dimensions support the internal construct validity of the 
instrument (Ware 1997; Fayers 2007 ). Items within each dimension that met these 
criteria were referred to as the scaling success rate. An alpha value of a dimension that 
is higher than the dimension‟s correlation to the other dimensions indicates that the 
dimension scores represent different aspects of HRQOL (Ware and Gandek 1998). The 
criterion-based validity, i.e. the instrument‟s capacity to discriminate between patients 
differing in symptom burden, was evaluated by comparing data from children 
diagnosed with ALL to those diagnosed with sarcoma.  
 
Study II 
Demographic and clinical characteristics of children undergoing treatment for cancer 
were analysed with regard to self-reported school attendance, HRQOL and reasons for 
school absence. 
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Study III 
Children undergoing cancer treatment were compared with respect to clinical and 
demographic characteristics and start of antimicrobial treatment during two observation 
periods of 19 days.  
 
Time to start of antimicrobial treatment was estimated by the Kaplan-Meier method 
(Kaplan 1958). Children not starting antimicrobial treatment during the observation 
period of 19 days were censored on the last day of the investigated period. Differences 
in time to start of antimicrobial treatment between children attending school and those 
not attending school were analyzed using the log-rank test (Kaplan 1958).  
 
Study IV 
The recorded telephone interviews were transcribed verbatim. The answers to the two 
open-ended questions were analyzed using content analysis (Graneheim and Lundman 
2004). Content analysis is a suitible instrument for analyzing and handling large and 
relatively unstructured data in view of meaning, symbolic qualities and expressive 
contents. To gain a sense of the whole the data analysis started with repeated readings 
of all the responses to each of the two open-ended questions. The process continued in 
an effort to search for sentences capturing key thoughts or concepts. These key 
thoughts or concepts were subsequently transformed into meaning units. The answers 
to the question “Because of your cancer experience, do you think things are different in 
school for you today compared to your peers?” were sorted into categories. The 
identified meaning units of the answers to the question “When thinking back on life 
during the time of your cancer treatment, what do you first think about?” were first 
divided into subcategories and then sorted into categories (Graneheim and Lundman 
2004).  
 
Table 2. Examples of categorization of statements 
Example of meaning units Subcategory Central characteristic of the 
subcategories 
Category 
“The worse time of my life and it 
was bad all the time” 
Emotionally 
distressing  
 
Statements describing the 
experience as troublesome 
A straining 
experience   
“The first treatment was hard. I felt 
sick and vomited and could not eat 
at all; it was really hard” 
Distressing 
adverse effects 
from treatment 
Descriptions of side effects 
from treatment, including 
fatigue, hair loss, nausea and 
vomiting, lack of appetite, 
mucositis and body changes  
 
 
 
PROCEDURES 
During initial cancer treatment (study I-III)  
Data were collected from January 2004 to November 2006 with the assistance of the 
national network of consultant nurses in paediatric oncology. Approximately 3 weeks 
after diagnosis, the consultant nurses contacted possible participants at the hospital and 
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presented both oral and written information about the study. Those who accepted 
participation received the first questionnaires at time for the first assessed week (T1). 
At the second (T2) and third assessment (T3), the questionnaire were either submitted 
to the participants at a scheduled hospital visit or sent home by mail. If the 
questionnaires were not returned within a week, families were reminded by telephone 
or by mail. The consultant nurses also collected additional data from the participants‟ 
medical records, both at the centre and in case of a co-operating local hospital.  
 
Follow-up 5 years after diagnosis (study IV) 
Survivors 
An information letter was sent to all eligible participants. The letter was addressed to a 
parent for participants aged 11-15 years, to the possible participant including a letter to 
the parent/parents for those aged 16 to 17 years and directly to participants aged 18 
years and above. Potential participants or parents were contacted by telephone within 2 
weeks after the letter was mailed; for those who accepted participation, a suitable time 
for the telephone-administered interview was agreed upon. Written reminders were sent 
when participants were difficult to reach. Written informed consent was obtained from 
participants and parents for participants <18 years of age and from participants aged 
≥18 years. The interviews were tape-recorded and responses to the structured questions 
(study-specific and for the dimension Independence in the DCGM-37) were written 
down.  
 
Comparison group 
The comparison group basically underwent the same procedure as the survivors. The 
interviews with structured questions were tape-recorded and responses were written 
down. Written consent for participants <18 years of age was obtained from the 
participants and parents; oral consent for participants aged ≥18 years was tape-recorded 
before the start of the interview.  
 
An episode of infection was defined as the individual period of use of oral or 
intravenous antimicrobial treatment with one or more antibiotic, antifungal or antiviral 
agents prescribed because of symptoms of infection. Any prescribed adjustment or shift 
in antimicrobial therapy during the period was not considered as a new episode. 
Antimicrobial treatment prescribed without symptoms of infection was considered as 
prophylaxis. Neutropenia was defined as one day or more with an ANC <0.5 x 10
9
/L.  
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ETHICAL CONSIDERATIONS 
Ethical approval was obtained from the Regional Ethical Review Boards in Umeå, 
Uppsala, Stockholm, Linköping, Göteborg and Lund for the study conducted during 
initial cancer treatment (2004-2006) and by the Regional Ethical Review Board in 
Stockholm for the follow-up study.  
 
Approaching families in a vulnerable position where a child is recently diagnosed with 
cancer requires extreme caution and wise discernment. The risk of causing harm to the 
children and their parents was weighed against the benefit of possible improvement in 
future care of children and adolescents with cancer. All children and their parents who 
were invited to participate were reassured that their decision regarding participation 
would not affect the child‟s care in any way.   
 
Furthermore, when approaching persons at follow-up (a median of 5 years after 
diagnosis), there is a risk that the interviews could evoke thoughts and feelings that the 
participants may find distressing. Before ending the interview, the researcher pointed 
out the possibility that troubling thoughts could emerge and in that case the respondent 
was invited to contact the researcher for advice where he or she could turn to for help. 
However, to be interviewed may also be perceived as an opportunity to talk about their 
former experiences. All participants were informed about confidentiality and the 
possibility to withdraw from the study at any time.   
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RESULTS 
STUDY I-IV 
Demographic and clinical characteristics of the participants in study I-IV are presented 
in Table 3. One difference was found between participants and non-participants in 
study I-III. Children diagnosed with Non-Hodgkin lymphoma were more likely not to 
attend the study. In Study IV no statistically significant differences were found between 
participating and non-participating survivors (Table 3), or between the survivors and 
the controls.  
 
Table 3. Demographic and clinical characteristics of participants and non-participants                                            
in study I-IV                                                
 Study I-III Study IV 
 Participants 
undergoing 
treatment 
n=101 
Non-
Participants 
 
n=44 
Survivors 
5 years after 
diagnosis 
n=63 
Non-
Participants 
 
n=29 
Gender, n (%)            
Female 42 (42) 16 (36) 26 (41) 10 (34) 
Male 59 (58) 28 (64) 37 (59) 19 (66) 
Age groups, n (%)  
        7-12 years  
      13-16 years 
 
56 (55) 
45 (45) 
 
20 (46) 
24 (54) 
  
12-17 years   37 (59)  
18-22 years   26 (41)  
School grade at diagnosis, 
median (range) 
    6 (1-9) 6 (1-9)   
Siblings living at home, n (%)                         91 (90)    
Siblings   59 (94)  
Diagnosis, n (%)     
Acute lymphoblastic 
leukaemia 
33 (33) 13 (30) 21 (32) 10 (34) 
Acute myeloid leukaemia                          5 (5) 3 (7) 3 (5) 1 (3) 
CNS
  
  tumours       16 (16)   5 (11) 10 (16) 2 (7) 
Non-Hodgkin‟s lymphoma                         12 (12)   11 (25)*   6 (10)   6 (22) 
Hodgkin‟s lymphoma                                9 (9) 3 (7)   6 (10)   4 (14) 
Sarcoma                                            17 (17) 4 (9) 10 (16)   3 (10) 
Rhabdomyosarcoma 5 (5) 2 (5) 3 (5) 2 (7) 
Other 
c
 4 (4) 3 (7) 4 (6) 1 (3) 
ª Tested for difference in proportions by Chi-square test or Fisher‟s exact test.  
*<0.05, **<0.01, ***<0.001 
 
c
 Neuroblastoma, Germ cells tumour, Soft tissue sarcoma (nerve), Sertoli leydig cell 
tumour, Synovial sarcoma, Teratoma and a mixed tumour.  
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SCHOOL SITUATION 
During initial cancer treatment 
School attendance significantly increased over the first 5 months of cancer treatment, 
with 47 (47%) of the 101 participating children attending school at least once during 
the first assessed week (T1) 1 week after the start of treatment and 71 (70%) 4 months 
later (T3). The median number of attended school days per child and week significantly 
increased during the first 5 months (Table 4). The most commonly reported reasons for 
absence from school and not meeting friends were hospital visits and fatigue (Table 4). 
A median number of 14 (T1), 17 (T2) and 8 (T3) children were on scheduled holiday 
during the three assessment periods. 
 
Table 4.  Self-reported school attendance in study II and reasons for being absent from 
school during 3-week periods in the first 5 months of cancer treatment (N=101)  
 T1 T2 T3 
Number of children attending school each day, median   27 36 52 
Number of days attending school, median    1   1   3*** 
Median number of children absent from school   59 48 42 
Reasons for absence from school, median    
  Hospital visit 31 27 18 
  Fatigue 14 11   9 
  Infection                                                                  5   5   4 
  Fear of being exposed to infections   4   2   3 
  Pain     1   2   1 
  Nausea                                                                     1   1   1 
  Other disease and treatment-related causes                       0   1   2 
  School-related reasons
a
                                              2   2   2  
  Fear of the reactions of others                                             2   1   1 
  Don‟t want to go to school   0   1   1 
  Miscellaneous   3   1   3 
 a
School-related reasons included the class performing activities outside school and the 
child having too much home work  
 
Sixteen children (16%) did not attend school at all during the studied weeks. Children 
with osteosarcoma were more likely not to attend school than children with other 
diagnoses (31% of the osteosarcoma patients vs. 10% of all other diagnoses combined, 
X
2
=9.71, p<0.01).  
 
Antimicrobial treatment 
Eighty-nine children were free from antimicrobial treatment at start of T1 and T2. 
Thus, these 89 children were included in the analysis to examine the association 
between school attendance and start of antimicrobial treatment.  
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Table 5. Differences in clinical characteristics in children free from antimicrobial treatment at start of potential school 
weeks, T1 (n=89) and T2 (n=89) in relation to start of antimicrobial treatment  
 
                    T1 (19 days)                T2 (19 days) 
   
Observation 
Started 
antimicrobial treatment 
 
Observation 
Started 
antimicrobial treatment 
 n n (%) n n (%) 
<13years 
>13years 
50 
39 
18 (36) 
  9 (23) 
51 
38 
14 (27) 
  6 (16) 
Girl  
Boy 
37 
52 
13 (35) 
14 (27) 
37 
52 
11 (30) 
  9 (17) 
Preschool-aged siblings                 
  No preschool- aged sibling 
16 
73 
  2 (13) 
25 (34) 
17 
72 
  5 (29) 
15 (21) 
 
Children attending school 
  Children not attending school 
 
47 
42 
 
  10 (21) 
    17 (40)* 
 
51 
38 
 
  9 (18) 
11 (29) 
 
Acute lymphoblastic leukaemia (ALL) 
 Not ALL  
 
30 
59 
 
      3 (10)** 
 24 (41) 
 
30 
59 
 
  5 (17) 
15 (25) 
Acute myeloid leukaemia (AML) 
  Not AML                      
3 
86 
  2 (67) 
25 (29) 
 4 
85 
        4 (100)** 
16 (19) 
Central nervous system tumours (CNS) 
  No CNS tumours 
15 
74 
    0 (0)** 
27 (36) 
14 
75 
 1 (7) 
19 (25) 
Non-Hodgkin‟s lymphoma (NHL)    
  Not NHL                      
9 
80 
   6 (67)* 
21 (26) 
10 
79 
  4 (40) 
16 (20) 
Hodgkin‟s lymphoma 
  Not Hodgkin‟s lymphoma                      
8 
81 
  2 (25) 
25 (31) 
9 
80 
 0 (0) 
20 (25) 
Sarcoma    
  Not sarcoma                    
16 
73 
      12 (75)*** 
15 (21) 
14 
75 
  5 (36) 
15 (20) 
Rhabdomyosarcoma 
  Not rhabdomyosarcoma                
4 
85 
  1 (25) 
26 (31) 
4 
85 
  1 (25) 
19 (22) 
Other diagnosesa 
  Not other diagnoses                    
4 
85 
  1 (25) 
26 (31) 
4 
85 
0 (0) 
20 (24) 
 
Chemotherapy alone 
  Not  chemotherapy alone                    
 
48 
41 
 
12 (25) 
15 (37) 
 
50 
39 
 
13 (26) 
  7 (18) 
Chemotherapy and surgery 
  Not chemotherapy and surgery                      
15 
74 
   10 (67)** 
17 (23) 
14 
75 
  3 (21) 
17 (23) 
Chemotherapy and radiotherapy 
  Not chemotherapy and radiotherapy                     
4 
85 
  1 (25) 
26 (31) 
5 
84 
0 (0) 
20 (24) 
Surgery and radiotherapy 
  Not surgery and radiotherapy                      
2 
87 
0 (0) 
27 (31) 
2 
87 
0 (0) 
20 (23) 
Chemotherapy, surgery and radiotherapy 
  Not chemo, surgery and radiotherapy                      
20 
69 
  4 (20) 
23 (33) 
18 
71 
 4 (22) 
16 (23) 
 
Children with ANCb<0.5 ≥1 day 
  Not ANCb<0.5 
 
40 
49 
 
      21 (53)*** 
  6 (12) 
 
37 
52 
 
      13 (35)*** 
  7 (13) 
Children with prophylactic oral antibiotics 
  No prophylactic oral antibiotics 
20 
69 
  3 (15) 
24 (35) 
15 
74 
  3 (20) 
17 (23) 
Children with G-CSF 
  No G-CSF 
5 
84 
  1 (20) 
26 (31) 
10 
79 
 4 (40) 
16 (20) 
 
SVPc 
  No SVP 
 
57 
32 
 
17 (30) 
10 (31) 
 
62 
27 
 
16 (26) 
  4 (15) 
CVCd 
  No CVC 
29 
60 
10 (34) 
17 (28) 
24 
65 
  4 (17) 
16 (25) 
PEGe 
  No PEG 
11 
78 
  5 (45) 
22 (28) 
9 
80 
  1 (11) 
19 (24) 
Differences in proportions tested by Chi-square statistics or Fisher‟s exact test:  *<0.05, **<0.01, *** <0.001                                                                                                                                                    
a
Neuroblastoma, Germ cells tumour, Sertoli leydig cell tumour, Synovial sarcoma 
b
Absolute neutrophil count 
  
 
c
Subcutaneous venous port, 
d
Central venous catheter, 
e
Percutaneous endoscopic gastrostomy  
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During the first observation period (T1) of 19 days, 27 (30%) of the 89 children started 
antimicrobial treatment (Table 5). Children starting antimicrobial treatment during T1 
attended school more seldom and their median number of attended days was lower (0, 
range 0 to 4 vs. 1, range 0 to 5; p-value=0.048) than children not starting antimicrobial 
treatment (Table 5). Furthermore, variables found to be more strongly associated with 
children starting antimicrobial treatment were the diagnoses sarcoma and NHL, 
neutropenia (21 (77%) vs. 19 (31%), p-value<0.001) and treatment with a combination 
of surgery and chemotherapy. During the second observation period (T2), 20 (22%) of 
the 89 children started antimicrobial treatment. The median number of attended school 
days was significantly lower in children starting antimicrobial treatment during T2 
compared with those not starting antimicrobial treatment (0, range 0 to 5 vs. 2, range 0 
to 5, p-value=0.022). Other variables showing a strong association with children 
starting antimicrobial treatment were AML and neutropenia (Table 5).  
 
Time to start of antimicrobial treatment was significantly longer among children 
attending school during T1 than those not attending school. However, no difference in 
time to start of antimicrobial treatment was observed during T2. 
 
The 47 antimicrobial treatments prescribed to children during T1 and T2 assessment 
periods were, with very few exceptions, intravenous antibiotics (91%).  
 
At T1 and T2, microbial cultures were obtained during 45 of the 47 episodes of 
antimicrobial treatment. Positive microbial findings were detected in 12 of the 45 
episodes of antimicrobial treatment (four in blood, five in urine, one in both blood and 
urine, one in both blood and faeces and one in secretion of vesicle). During T1, none of 
the six microbial blood cultures in children attending school was positive and in 1 of 15 
children not attending school. The corresponding number of positive blood cultures 
during T2 was one of six in children attending school and four of nine in those absent 
from school. 
 
Follow-up 4-6 years after diagnosis 
Fifty-three (84%) of the survivors and 205 (80%) of the controls were currently in 
education. The male survivors were (p<0.05) more often currently in education than 
were the male controls. The distribution of type and level of education did not differ 
between the survivors and controls. Furthermore, the majority of the participants 
(survivors and controls) considered school to be important in their lives though to a 
somewhat lower extent in the survivors (47, 89%. vs. 198, 97%, p=0.019). Fifty-one 
percent of the survivors and 42% of the controls stated that they had not been absent 
from school during the past month and the majority in both groups reported absence 
ranging between 0-3 days during the past month.  
 
Fifty of the 53 survivors currently in education answered the question “Because of your 
cancer experience, do you think things are different in school for you today compared 
to your peers?” The answers were grouped into seven categories. Sixty-two per cent of 
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the survivors described the situation in school as basically the same compared to peers, 
categorized as „More or less like anyone else‟. Twenty percent of the survivors 
described decreased strength and difficulties to walk and run categorized as 
„Difficulties getting around and sporting‟ and 10% mentioned deficiencies in school 
work due to problems with memory, concentration and being slow, categorized as 
„Difficulties related to cognition dysfunction. A small number of participants cited 
falling behind, categorized as „Impact on school results‟. Furthermore, statements made 
by 10% of the survivors described feelings of appreciation and of being more mature 
compared with their peers and were categorized as „Different view of life‟ and a few 
stated that they had better school results than their peers, characterized as „good school 
results‟. Some survivors contributed to more than one category in that they reported 
having more than one difference in school compared with their peers.  
  
Sixty-one (97%) of the 63 survivors answered the question “When thinking back on life 
during the time of your cancer treatment, what do you first think about?” The content 
analysis of the answers resulted in meaning units grouped into 15 subcategories that 
were sorted into six categories. Some survivors expressed thoughts contributing to 
more than one subcategory.   
 
Table  6. Survivors‟ (n=61) thoughts when thinking back on life during  
the time of cancer treatment by subcategories and categories  
Subcategory N Category 
Emotionally distressing  36 A straining experience   
Disturbing side effects 
Extensive and strenuous treatment 
Realizing that it was cancer 
School attendance 16 School and friends 
Being away from friends 
Friends as resource  
Keeping up with school work  
Unsupportive friends    
Fear of being different 
 14 Being in hospital 
 7 Few thoughts from time of treatment    
Positive aspects/impact  
Positive memories 
6 Positive experiences 
 3 Social comparison 
 
Slightly more than 25% of the survivors mentioned issues of how school and 
relationship to friends was affected by illness and treatment, categorized as „School and 
friends‟. Statements about school included in this category concerned school attendance 
and absence, as well as the struggle to keep up with school work during treatment. 
Statements about friends included descriptions of being away from friends, friends 
showing concern, friends not knowing about what had happened and fear of being 
different. Most frequently mentioned statements (60% of the survivors) were 
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descriptions and memories of the difficult period during treatment, categorized as „A 
straining experience‟. This category includes descriptions of the emotionally distressing 
cancer experience, disturbing side effects and the burdens associated with intensive 
therapy. Almost 25% of the survivors described having to stay at hospital for long 
periods and pointed out different activities (e.g., treatment, playing computer games 
and expressing opinions about meals) that they were engaged in during their hospital 
stay, categorized as „Being in hospital‟. More than 10% declared that they rarely, if 
ever, thought about the time when they had cancer, categorized as „Few thoughts from 
time of treatment‟.  
 
No significant difference was found between the survivors and controls in perceived 
susceptibility to infections compared to peers.   
 
HEALTH-RELATED QUALITY OF LIFE   
During initial cancer treatment 
Data quality and psychometric properties of the DCGM-37 (study I) 
Data quality was acceptable with the percentage of missing items by dimension below 
6% (range 0 to 5.3%). The largest number of missing items was found in the dimension 
Social Exclusion (Table 8). Reasons for not responding to an item were seldom 
reported. Occasionally, the reason for not answering items in the school dimension was 
explained by not having been in school while the reason for not answering items in the 
Treatment dimension was explained in terms of not taking any medication.  
 
Table 8. Psychometric statistics from study I for the DCGM-37 in Swedish children on 
cancer treatment (pooled data, i.e. T1 + T2, n=170) 
a 
Number of item-to-other dimension correlations that are stronger than the corrected 
item-total correlation within a dimension / Total number of discriminant validity tests 
(i.e. number of items by number of dimensions minus 1) expressed as a percentage. 
 
The legitimacy of adding up items to generate a total score was supported by the data, 
i.e. item means and standard deviations within the respective dimensions were roughly 
equivalent (Table 9). However, all but one corrected item-total correlation exceeded 
0.30 and the corrected item-total for item 31 in the dimension Social Inclusion was 
0.28. Moreover, in all but six instances (items 10, 11, 22, 26, 30, 31) the item-total 
correlation was >0.40 (Table 8). The distribution of dimension scores was supported in 
that floor effects ranged from 0 to 2.4% and ceiling effects from 0 to 2.9%, with the 
 
 
Dimension 
 
 
n
 
 
Missing 
items, 
range  (%) 
 
Range of item mean 
(SD)   
Floor/ 
Ceiling 
effect 
 (%) 
 Item-to-own 
dimension 
correlation 
(range) 
Item-to-other 
dimension 
correlation 
(range) 
Scaling 
success 
(%)
 a
 
Independence 170 0-4 (0) 3.03-3.89 (0,96-1,18) 0.6/ 0 0.43-0.68 0.15-0.60 93 
Physical Limitation  169 0-2 (0.6) 3.25-3.94 (1,02-1,34) 0/ 0 0.32-0.66 0.19-0.58 87 
Emotion
  
 165 3-5 (2.9) 2.88-3.53 (0,97-1,22) 0/ 1.2  0.54-0.70 0.25-0.65 100 
Social Exclusion 161 1-13 (5.3) 3.31.4.51 (0,68-1,22) 0/ 2.9  0.35-0.63 0.09-0.60 90 
Social Inclusion 168 0-6 (1.2) 3.02-4.35 (0,83-1,16) 0/0.6  0.28-0.66 -0.01-0.65 73 
Treatment 164 4-8 (3.5) 3,35-4.02 (1,14-1,60) 2.4/10.0  0.54-0.77 0.14-0.47 100 
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exception of the Treatment dimension, which had a larger, but still acceptable ceiling 
effect of 10% (Table 8). Reliability for all dimension scores exceeded the 
recommended minimum of 0.70 and three dimension scores exceeded the preferred 
value of 0.80 (Table 9).Multi-trait scaling analyses supported the grouping of items into 
dimensions for 26 of the 36 items in that their corrected item-total correlations 
exceeded the correlations with other dimension scores. Scaling success rates ranged 
from 73 to 100% (Table 8).  
 
Self-reported HRQOL (study I-II)  
The DCGM-37 was completed by 83 participants at T2 and by 87 at T3. All scales in 
the DCGM-37 had Cronbach‟s alpha coefficients above 0.70 (range 0.72 to 0.87). 
HRQOL for the total group did not significantly change between T2 and T3 in any of 
the dimensions (Table 9).  
 
Table 9.  Self-reported HRQOL as measured by the DCGM-37 at 2.5 months (T2), 5 months 
(T3) and the pooled version (T1 + T2) after the start of cancer treatment, (study I-II)     
 
DCGM-37 scales T2 n=83 T3 n=87 Pooled version n=170 
 Mean
a
  
(SD) 
Reliability 
(α) 
Mean
a
 
(SD) 
Reliability 
(α) 
Mean
a
 
(SD) 
Reliability  
(α) 
Independence  60.3 (19.0) 0.80 60.5 (20.1) 0.83 60.4 (19.5) 0.81 
Physical Limitation                                                  51.1 (18.3) 0.72 55.4 (21.3) 0.78 53.1 (19.6) 0.76 
Emotion      57.0 (19.9) 0.82 60.3 (19.4) 0.85 58.5 (19.9) 0.84 
Social Exclusion    69.4 (17.6) 0.73 68.3 (18.4) 0.76 68.5 (17.7) 0.76 
Social Inclusion    61.7 (17.8) 0.72 62.3 (17.0) 0.70 61.9 (17.3) 0.71 
Treatment    65.1 (25.2) 0.85 63.7 (26.8) 0.87 64.0 (25.8) 0.87 
ª Scores range from 0 to 100, with higher scores representing a better HRQOL. 
 
Comparing the scores of the boys and girls at T2 and T3 revealed that the Girls scored 
worse on four of the six DCGM-37 scales (Independence, Physical limitation, Emotion 
and Social exclusion) at both T2 and T3. Self-reported HRQOL did not differ between 
the two age groups (7-12 years vs. 13-16 years), with the exception of the Physical 
Limitation dimension, which was rated significantly higher among the adolescents than 
among the younger group. All effect sizes were either low or medium. Mean value 
differences and effect sizes were found between children with ALL and children with 
sarcoma. The sarcoma patients scored significantly lower in all dimensions than the 
ALL patients and all effect sizes were large.  
 
The results of the partial correlations after controlling for sex between days of school 
attendance and the measured HRQOL dimensions revealed positive coefficients in all 
dimensions. At T2, all but two coefficients were significant and at T3 all coefficients 
except one were significant. All correlation coefficients but one were of medium or 
large size at T3:  Independence: T1 0.32, T2 0.50; Physical Limitation: T1 0.32, T2 
0.50; Emotion: T1 0.03, T2 0.34; Social Exclusion T1 0.27, T2 0.37; Social Inclusion 
T1 0.30, T2 0.42; Treatment: T1 0.03, T2 0.27. 
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Follow-up 4-6 years after diagnosis 
The results from the DCGM-37 revealed that survivors rated the Independence 
dimension statistically significantly higher a median of 5 years after diagnosis 
compared with the corresponding results during treatment (Table 10). Furthermore, at 
the 5-year follow-up post-diagnosis, the survivors rated their independence as being 
higher than the controls. No gender difference in mean values of self-rated 
independence was seen among the survivors.  
 
Mean value differences were observed on each of the six items of the Independence 
dimension between time of initial treatment and follow-up a median of 5 years after 
diagnosis. All items, except the first item (Are you confident about your future?) were 
scored higher at follow-up than at the time of initial treatment. This first item was rated 
lower at follow-up than at the time of initial treatment (Not presented).  
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DISCUSSION  
The overall results of this thesis show that even though school attendance and HRQOL 
is diminished in children undergoing initial cancer treatment, survivors 4-6 years later 
appear to get along well despite physical and cognitive limitations. Furthermore, the 
findings do not indicate that school attendance is a risk factor for development of 
infections that require antimicrobial treatment, during initial cancer treatment.  
 
DURING INITIAL CANCER TREATMENT  
School attendance was shown to be limited close after starting cancer treatment, mostly 
due to hospital visits and fatigue. Furthermore approximately 30% were undergoing 
antimicrobial treatment due to infections. It is well-known that children in addition to 
start of chemotherapy and/or radiotherapy are affected by symptoms from the illness as 
well as side effects from treatment (Hedström, Haglund et al. 2003; Hedström, 
Ljungman et al. 2005; Moody 2006; Wicki, Keisker et al. 2008). Being diagnosed with 
cancer and in a new unfamiliar situation with different treatments and side effects may 
affect the desire to go to school. Still, a median of 5 years after diagnosis, more than 
half of the survivors think back on the time of treatment as a straining experience. Five 
months after start of cancer treatment (T3) the children appear to somewhat have 
adjusted to having cancer reflected by an increase in school attendance (Stewart 2003). 
However, in line with findings from other studies, self-reported HRQOL scores did not 
increase during initial cancer treatment (Eiser, Eiser et al. 2005; Hedström, Ljungman 
et al. 2005; Landolt, Vollrath et al. 2006; Engelen, Koopman et al. 2011) and were low 
compared with norms (The European DISABKIDS Group 2006). Already after a 
couple of months‟ treatment (T2 and T3), many of the children and adolescents may be 
free from initial symptoms of disease because of quick response from treatment 
(Smiths 31996). This may be one explanation for the observed increase in school 
attendance at T3 (5 months after start of treatment) and the decrease in number of 
antimicrobial treatments the first six months (data not presented). Although some form 
of normalcy may have returned to the lives of these children 5 months after start of 
cancer treatment, life is still mostly focused on disease and treatment and the reported 
reasons for school absence were still mainly disease-related.  
 
School attendance did not appear to be a risk factor for start of antimicrobial treatment 
due to infection, a finding consistent with one of the few studies that have investigated 
the relation between social interaction and the risk of acquiring an infection among 
children with cancer (Tabori, Jones et al. 2007). In accordance with other reports 
(Bodey 1986; Auletta, O'Riordan et al. 1999; Klaassen, Goodman et al. 2000; Haupt, 
Romanengo et al. 2001; Christensen, Nielsen et al. 2005; Nam, Kim et al. 2010), we 
identified neutropenia, certain diagnoses (sarcoma, NHL and AML) and type of 
treatment (chemotherapy combined with surgery) as factors related to the start of 
antimicrobial treatment. Yet, we did not collect all data on risk factors suggested to be 
related to infections (e.g. intensity of treatments and nutrition status) (Haupt, 
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Romanengo et al. 2001; Wicki, Keisker et al. 2008; Israels, van de Wetering et al. 
2009) and thus it is difficult to draw firm conclusions from our results.  
 
4-6 YEARS AFTER DIAGNOSIS 
At follow-up, four to six years after diagnosis, no major differences were found 
concerning the school situation between the survivors of childhood cancer and an age 
matched comparison group drawn from the general population. Furthermore, self-
reported independence, a dimension included in the mental domain of HRQOL, was 
rated statistically significant better than while undergoing treatment as well as 
compared to the controls. The finding of diminished HRQOL in children on cancer 
treatment is in line with results from several studies (De Clercq, De Fruyt et al. 2004; 
Jörngarden, Wettergren et al. 2006; Jörngården, Mattsson et al. 2007; Engelen, 
Koopman et al. 2011). Although the majority of the survivors remembered the time of 
treatment as a straining period and several persons described difficulties in school 
because of the cancer experience, the overall impression is that most of them function 
quite well in school as well as with regard to perceived autonomy and the possibility to 
live without impairments approximately 5 years after treatment.   
 
During initial treatment, children diagnosed with osteosarcoma was showed to be more 
vulnerable with more school absence, poorer HRQOL and more treated infections than 
children with other diagnoses. These results support the findings of previous research 
showing that adolescents diagnosed with sarcoma, close to time for diagnosis score 
their HRQOL significantly lower compared to those with AML (Hinds, Billups et al. 
2009). However, there is nothing in the results from the follow-up study to suggest that 
this difference between diagnoses remains with the passage of time. 
 
METHODOLOGICAL CONSIDERATIONS 
There are some threats to internal and external validity of the studies included in this 
thesis that need to be mentioned.  
 
Internal validity refers to the likelihood that the results of a study may be explained by 
the independent variable(s) and not by plausible rival variables. The most obvious 
threat to internal validity is selection bias (Kazdin 2003), which in this study has been 
controlled by including all children diagnosed with every type of childhood cancer 
during a certain time span and by subsequently inviting the same group to the follow-up 
study. Research on childhood cancer often excludes children with tumours of the CNS 
(Lähteenmäki, Huostila et al. 2002; Mört, Salanterä et al. 2011)  which was not the case 
in this study, children with CNS tumours represented 16% of the sample in all the four 
studies, which is considered representative of the Swedish child cancer population. A 
further strength of the follow-up study was the inclusion of an age matched comparison 
group drawn from the general population which was randomly assigned making it 
possible to compare findings to young people without cancer experience (Kazdin 
2003). Attrition may also affect the possibility to draw valid conclusions in a 
longitudinal study. With one exception the analysis of attrition did not reveal any 
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significant differences in age, gender and diagnoses between participants and non-
participants during initial treatment and at follow-up. During initial treatment children 
diagnosed with NHL were more likely to be non-participants. Accepted response rates 
for investigations concerning special groups have been suggested to be about 75-85% 
(Trost 2007) and thus our response rate of 70% during initial treatment and 68% at 
follow-up must be considered relatively low. We do not know whether those who chose 
not to participate had a better or worse HRQOL and if they perceived school differently 
than those who participated. Perhaps, those who decided to participate did so because 
they were more troubled due to the cancer experience, while those who decided not to 
participate had less problems. On the other hand, one might also expect that those who 
wanted to move on with life decided not to participate. Answers from general 
questionnaire surveys however, may vary from 50 to 75% whereas the response rate in 
the comparison group, 54%, can be considered acceptable.  
Threats to internal validity include the risk that the participant, after having completed a 
questionnaire on the next occasion recognize the questions and therefore answer 
without reflecting. This may have been the case when assessing HRQOL with the 
DCGM-37 and school attendance. However, when planning the initial studies we 
considered 2.5 months as a plausible period to avoid this threat especially when taking 
the present intense situation into account. Another possible weakness may be that the 
data on school attendance is entirely based on self-reports. Furthermore, we used a 
study-specific questionnaire for collection of data regarding school attendance which 
had not been psychometric evaluated. Furthermore, data was incomplete with regard to 
the exact number of days of school attendance because we only asked for number of 
lessons the child daily attended. One lesson or more of school attendance during 1 of 
the 5 days of observation was thus considered as being in attendance. However, the 
results of school attendance were found to be sensitive for change detecting an increase 
in attendance over time in an expected direction. In study III if possible the most 
optimal would have been to monitor school attendance and antimicrobial treatments 
throughout the study period of six months. Furthermore, we have not studied the 
incidence of new cancer treatments during the 14 days of follow-up which also may 
have influenced the start of antimicrobial treatment during these days.  
The lack of a comparison group consisting of healthy children in study I-III limits the 
possibility to draw valid conclusions regarding the level of school attendance. 
However, it is clear that absenteeism in our studies is higher than the average rate for 
school children in Sweden. Another threat to internal validity is the occurrence of any 
internal or external events that may affect the outcome. An example of „history‟ that 
may affect the results is relapse of the cancer which some of the survivors described. 
However, we lack information on how many of the survivors that had experienced a 
relapse. One way to deal with this possible threat would have been to ask questions at 
the follow-up interview about major changes in life during the time that had passed 
since the initial treatment. Still, maturation and response shift may be a problem in the 
comparison between the scores of self-reported Independence during initial treatment 
and at follow-up (Kazdin 2003). Although the wording of the questions in the 
Independence dimension is exactly the same, they may have changed in meaning over 
time because of the participants‟ changed values and expectations.  
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External validity refers to the extent that the results of a study are generalizable to other 
contexts and circumstances (Kazdin, 2003). The present study is a national cohort study 
that increases the possibility to generalize the results to other groups of children beyond 
the same conditions in the Western world provided that accurate analysis of attrition is 
performed. To increase external validity the follow-up interviews were performed by 
more than one person.  
 
The possibility to draw valid inferences may be affected by the low statistical power. 
Small subgroups increases the probability that the results will incorrectly show no 
differences between groups (Type II error) (Kazdin 2003). Effect sizes were calculated 
to highlight the clinical importance of potential differences in means. An important 
factor for statistical conclusion validity is the reliability of the measures. For 
measurement of HRQOL the standardized DCGM-37 was used (The European 
DISABKIDS Group 2006) which in results from pilot testing in children with different 
chronic conditions have denoted satisfactory internal consistency for all dimensions 
(The European DISABKIDS Group 2006; Simeoni, Schmidt et al. 2007) and construct 
validity, as well as convergent and discriminant validity (Simeoni, Schmidt et al. 2007). 
To further examine the validity we evaluated data quality and psychometric properties 
of the DCGM-37 in children with cancer. Although the results show that the 
dimensionality is not optimal we consider that the DCGM-37 is a feasible instrument 
when used in children with cancer. Continued psychometric evaluation with Rasch, 
item-response theory or confirmatory factor analyses is however recommended. 
 
NURSING IMPLICATIONS 
When a child is undergoing treatment for cancer, the risk of a limited contact with 
school and friends is imminent. The paediatric oncology nurse has an important role in 
providing guidance and support to promote close contact between the family and 
school. When it is advisable and no risk for infection is evident, school attendance 
should be encouraged. To fulfil this task the nurse needs knowledge about the 
importance of maintaining an active social life, including school attendance during 
childhood cancer treatment. Our results showing a positive relation between school 
attendance and HRQOL and the lack of an association between school attendance and 
antimicrobial treatment may be encouraging for nurses in clinical practice. Hopefully it 
enables them to dare to recommend school attendance when the children‟s general 
condition is good. The results may facilitate understanding of individual aspects of 
experiences of having cancer is perceived in a longer perspective which may be 
important for health care professionals involved in the care of children. 
  
One of the response options possible to record as reason for school absence was “fear 
of others reactions”. This option was rarely chosen which also may indicate a benefit 
from school attendance and visits by the consultant nurses close to time for diagnosis. 
These results contrasts to earlier findings whereas bullying was retrospectively 
perceived by children as their main problem during cancer treatment (Lähteenmäki, 
Huostila et al. 2002) but are more in line with recent findings where adolescents with 
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cancer were found to score better HRQOL than a control group on an HRQOL 
dimension including bullying (Engelen, Koopman et al. 2011). Network-focused 
nursing is another nursing programme with the aim to support adolescents with cancer 
and their families in order to establish, maintain and make use of their social network. 
This programme was developed by Danish nurses working in an oncology section with 
young persons (15-22 years) mostly diagnosed with sarcoma and testicular cancer 
(Olsen and Harder 2010). The concept was developed in a grounded theory study of 
nurses, teenagers and young adults and their families and focuses on the teenagers and 
young adults need for social support. The nursing programme includes network 
meetings held by nurses where persons in the social environment of the adolescent and 
family are invited to receive information are included in the concept. The teenagers are 
supported in taking an active part in the decision as to which persons should be invited 
to the meeting. In agreement with my own clinical experience adolescents are often 
described as a special vulnerable group and several reports advocate special youth units 
for adolescents and young adults (Whelan 2003; Olsen and Harder 2010). By extending 
the system of consultant nurses to network-focused nursing, preferably in a special 
youth unit, the situation of children and adolescents with cancer would be greatly 
improved. 
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SUMMARY AND CONCLUSIONS 
The DCGM-37 is considered to be a feasible and reliable instrument for use among 
children on cancer treatment, although the dimensionality was not entirely supported. 
During initial cancer treatment children were frequently absent from school, which was 
primarily due to hospital visits and fatigue. In addition, self-reported HRQOL was 
diminished, especially among the girl participants. We found a positive relation 
between school attendance and HRQOL and furthermore, school attendance did not 
appear to be a risk factor for start of antimicrobial treatment. Children with 
osteosarcoma, in comparison with children with other diagnoses, seem to be more 
vulnerable during initial treatment with regard to school attendance, HRQOL and 
infections. Furthermore, the majority of the survivors get along well in school in terms 
of autonomy and the possibility to live without impairments approximately 5 years after 
diagnosis. However, a significant part of the survivors described present difficulties in 
school related to having had cancer. Research is recommended, preferably a larger 
prospective international multicentre study regarding school attendance among children 
with cancer, including measurement of HRQOL and established protocols for 
antimicrobial treatment. Furthermore, continued psychometric evaluation of DCGM-37 
when used in children with cancer including more conclusive analyses such as Rasch, 
item-response theory or confirmatory factor analyses are suggested. 
 
The present findings underscore the importance of psychosocial care for children 
during initial cancer treatment as well as after completed therapy. Furthermore, given 
the social benefits of school attendance, our findings support that children with cancer 
are encouraged to attend school. Since the follow-up study is focused on the situation in 
school we cannot comment on the survivors‟ total life situation including relations 
within the family and partnering. Furthermore, as the time of the follow-up was 
relatively short it is not possible to draw conclusions about long-term outcome of the 
school situation. Continued follow-up of all of survivors of childhood cancer is 
therefore essential. Furthermore, continued research, preferably a register-based study 
that includes a large cohort to investigate school performance, level of education, 
choice of career and sick leave from work in long-term survivors of childhood cancer, 
is recommended.  
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SUMMARY IN SWEDISH 
När ett barn behandlas för cancer påverkas ofta skolsituationen både under och efter 
behandlingen. En bidragande orsak till skolfrånvaro är bristen på kunskap om risken för 
infektion under pågående behandling för cancer. Skolsituationen, inklusive skolnärvaro 
och hälsorelaterad livskvalitet bland barn med cancer har dock studerats i begränsad 
omfattning. Det saknas dessutom valida instrument för mätning av hälsorelaterad 
livskvalitet för denna grupp av barn. Det övergripande syftet med denna avhandling var 
därför att undersöka skolsituationen och hälsorelaterad livskvalitet för skolbarn (7-16 
år) under den inledande cancerbehandlingen och 4 till 6 år efter diagnos.  
 
Avhandlingen har en longitudinell design och innefattar fyra studier av en kohort 
skolbarn (n=126) som fått en cancerdiagnos och påbörjat behandling med kemoterapi 
och/eller strålbehandling. Under den inledande cancerbehandlingen insamlades data en 
månad (T1), 2,5 månader (T2) och 5 månader (T3) efter påbörjad behandling med ett 
studie-specifikt frågeformulär för att undersöka skolnärvaro och ett standardiserat 
instrument för mätning av hälsorelaterad livskvalitet, dvs. the Disabkids chronic 
generic module (DCGM-37). I studie I utvärderades datakvalitet och de psykometriska 
egenskaperna hos DCGM-37. Studie II följde skolnärvaron och hälsorelaterad 
livskvalitet under tre olika veckor de första 5 månaderna av cancerbehandling. I studie 
III deltog barn som var utan antimikrobiell behandling dagen innan de två 
observationsperioderna (19 dagar) under den inledande cancerbehandlingen. 
Demografiska och kliniska data samt skolnärvaro analyserades med avseende på 
relation till påbörjad antimikrobiell behandling. Cirka 5 år efter diagnos accepterade 63 
av de som behandlats för cancer i barndomen att delta i en uppföljande studie av deras 
skolsituation och självskattad självständighet (studie IV). I studie IV insamlades data 
via telefonintervjuer med både öppna och strukturerade frågor samt DCGM-37 
dimensionen Independence. Svaren på de strukturerade frågorna från de som 
behandlats för cancer i barndomen jämfördes med svaren från en åldersmatchad 
kontrollgrupp från den allmänna befolkningen (n=257).  
 
Utvärdering av DCGM-37:s datakvalitet och psykometriska egenskaper (studie I) visar 
att det är ett användbart instrument för barn med cancer, även om uppdelningen i 
dimensioner inte är helt optimal. Resultaten från studie II-III visade en signifikant 
ökning av skolnärvaron under de första 5 månaderna av den initiala cancerbehandling 
samtidigt som den självrapporterade hälsorelaterad livskvalitet var låg, särskilt bland 
flickorna, vilket inte förändrades under studietiden. Dessutom påvisades ett positivt 
samband mellan hälsorelaterad livskvalitet och skolnärvaro. Sjukhusbesök och trötthet 
var de två viktigaste angivna orsakerna till skolfrånvaro. Barn som gick i skolan 
rapporterade bättre hälsorelaterad livskvalitet och verkade inte utveckla fler infektioner 
än barn som inte gick i skolan. Resultaten från studie IV, cirka 5 år efter diagnos, 
visade att trots att 62% av de unga som behandlats för cancer i barndomen ansåg att 
deras skolsituation var mer eller mindre densamma som deras kamraters situation så 
rapporterade en betydande del svårigheter i skolan på grund av fysiska och kognitiva 
begränsningar. Vid uppföljningen, skattade de som behandlats för cancer i barndomen 
sin självständighet (dimensionen Independence) betydligt högre än de gjorde under den 
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inledande behandlingen, cirka 5 år tidigare och deras skattningar var också betydligt 
högre än kontrollgruppens. De aktuella resultaten understryker vikten av psykosocialt 
omhändertagande och omsorg av barn som genomgår cancerbehandling och av fortsatt 
uppföljning efter avslutad behandling. Med tanke på de sociala fördelarna med 
skolgång stöder våra resultat att skolnärvaro under behandling för cancer uppmuntras. 
På grund av den relativt korta uppföljningstiden är det inte möjligt att dra slutsatser om 
hur skolsituationen ser ut på längre sikt efter behandling för cancer i barndomen.  
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